Indomethacin Extended-Release Capsules recalled for cGMP deviations
Amerisource Health Services LLC is recalling Indomethacin Extended-Release Capsules 75 mg due to cGMP (current Good Manufacturing Practice) deviations. The recall affects 21 cartons distributed nationwide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The FDA classified this as Class II, and the source text does not report any illnesses or injuries. The recall is based on manufacturing process deviations (cGMP), which represents a potential risk but without documented adverse health consequences.
Plain-English summary
Amerisource Health Services LLC, operating as American Health Packaging in Columbus, Ohio, is voluntarily recalling Indomethacin Extended-Release Capsules, USP, 75 mg due to cGMP deviations. The affected product is sold in cartons containing 30 capsules (3 x 10 blister cards) per carton.
The recall involves Lot #1021950 with expiration date 11/30/2026, with NDC 68084-411-21 (carton) and NDC 68084-411-11 (blister card). A total of 21 cartons were distributed nationwide in the USA.
Patients taking this medication should consult their healthcare provider before discontinuing use. Pharmacists and healthcare providers should quarantine and return the affected lot to the distributor or contact the recalling firm for instructions.
The recalled product
- Product
- INDOMETHACIN (INDOMETHACIN)
- Brand
- INDOMETHACIN
- Manufacturer
- Amerisource Health Services LLC
- Hazard
- Affected units
- 21
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 1021950
- Exp. 11/30/2026
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · INDOMETHACIN
- ModerateIndomethacin Extended-Release Capsules Recalled for cGMP Deviations
FDA (Drugs) · 2025-05-28
- ModerateGlenmark Pharmaceuticals Recalls Indomethacin Capsules for Manufacturing Deviations
FDA (Drugs) · 2025-04-16
- ModerateIndomethacin Extended-Release Capsules Recalled Due to Failed Dissolution Specifications
FDA (Drugs) · 2024-09-04
- HighPrescription Drug Indomethacin Recalled Due to Label Mix-Up
FDA (Drugs) · 2023-12-06
- ModerateHetero Labs Recalls Indomethacin Capsules Due to Deformed or Clumped Units
FDA (Drugs) · 2018-08-08
Same manufacturer · Amerisource Health Services LLC
See all →- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets 50 mg Recalled for API Cross-Contamination
FDA (Drugs) · 2026-05-27
- HighMeclizine hydrochloride 12.5 mg tablets recalled after failing tablet specifications
FDA (Drugs) · 2026-04-01
- HighOxycodone blister cards recalled over seals that let tablets fall out
FDA (Drugs) · 2026-02-18
- HighUnit dose prazosin 2 mg cartons recalled over nitrosamine impurity
FDA (Drugs) · 2025-11-05
Same hazard · cGMP deviation
See all →- SevereCinacalcet Tablets Recalled for cGMP Deviations
FDA (Drugs) · 2026-07-08
- HighCinacalcet Tablets Recalled for N-Nitroso Impurity Exceeding Limits
FDA (Drugs) · 2026-07-08
- ModerateFentanyl Citrate Injectable Solution Recalled for cGMP Deviations
FDA (Drugs) · 2026-05-06
- SevereCarboxymethylcellulose Sodium Ophthalmic Gel recalled for sterility concerns
FDA (Drugs) · 2025-05-14
- SevereArtificial Tears Eye Drops Recalled for Manufacturing and Sterility Issues
FDA (Drugs) · 2025-05-14